Composition of certain financial statement captions |
| | | | | | | | | (In thousands) | March 31, 2015 | | December 31, 2014 | Accounts receivable, net | | | | Accounts receivable | $ | 20,755 |
| | $ | 21,875 |
| Less: allowance for doubtful accounts | (1,691 | ) | | (1,906 | ) | | $ | 19,064 |
| | $ | 19,969 |
| Inventories, net | | | | Finished products | $ | 14,349 |
| | $ | 12,116 |
| Work in-process | 891 |
| | 1,011 |
| Raw materials | 3,638 |
| | 4,116 |
| Less: inventory reserve | (554 | ) | | (639 | ) | | $ | 18,324 |
| | $ | 16,604 |
| Prepaid expenses and other current assets | | | | Prepaid supplies | $ | 1,319 |
| | $ | 1,123 |
| Prepaid insurance | 1,041 |
| | 968 |
| Other receivables | 733 |
| | 669 |
| Taxes recoverable | 1,968 |
| | 2,417 |
| Other | 3,384 |
| | 4,212 |
| | $ | 8,445 |
| | $ | 9,389 |
| Intangible assets, net: | | | | Technologies | $ | 52,167 |
| | $ | 52,508 |
| Customer relationships | 21,943 |
| | 22,108 |
| Product registrations | 8,224 |
| | 8,763 |
| Trade names | 3,417 |
| | 3,483 |
| Covenants not to compete | 8,618 |
| | 8,639 |
| Other | 991 |
| | 1,079 |
| Less: accumulated amortization | (35,928 | ) | | (33,931 | ) | | $ | 59,432 |
| | $ | 62,649 |
| Accrued expenses: | | | | Taxes payable | $ | 3,008 |
| | $ | 77 |
| Deferred revenue | 74,789 |
| | 4,185 |
| Clinical trials | 9,620 |
| | 8,643 |
| Professional fees | 1,624 |
| | 1,860 |
| Employee benefits | 6,495 |
| | 4,127 |
| Contingent consideration | 52,838 |
| | 27,352 |
| Other | 10,389 |
| | 14,668 |
| | $ | 158,763 |
| | $ | 60,912 |
| | | | |
| | | | | | | | | (In thousands) | March 31, 2015 | | December 31, 2014 | Other long-term liabilities: | | | | Contingent consideration – OPKO Renal | $ | 18,841 |
| | $ | 36,529 |
| Contingent consideration – OPKO Health Europe | — |
| | 254 |
| Contingent consideration – OPKO Diagnostics | 4,375 |
| | 6,992 |
| Contingent consideration – CURNA | 457 |
| | 440 |
| Mortgages and other debts payable | 2,185 |
| | 2,434 |
| Deferred tax liabilities | 166,922 |
| | 167,153 |
| Deferred revenue | 214,017 |
| | 2,526 |
| Other | 3,368 |
| | 1,030 |
| | $ | 410,165 |
| | $ | 217,358 |
|
|
Schedule of goodwill |
The following table reflects the changes in Goodwill during the three months ended March 31, 2015. | | | | | | | | | | | | | | | | | | 2015 | (In thousands) | Balance at January 1st | | Acquisitions | | Foreign exchange | | Balance at March 31th | Pharmaceuticals | | | | | | | | CURNA | $ | 4,827 |
| | $ | — |
| | $ | — |
| | $ | 4,827 |
| OPKO Mexico | 100 |
| | — |
| | (3 | ) | | 97 |
| OPKO Chile | 5,283 |
| | — |
| | (175 | ) | | 5,108 |
| OPKO Health Europe | 8,013 |
| | — |
| | (859 | ) | | 7,154 |
| FineTech | 11,698 |
| | — |
| | — |
| | 11,698 |
| SciVac | 1,553 |
| | — |
| | (36 | ) | | 1,517 |
| OPKO Renal | 2,069 |
| | — |
| | — |
| | 2,069 |
| OPKO Biologics | 139,784 |
| | — |
| | — |
| | 139,784 |
| Diagnostics | | | | | | | | OPKO Diagnostics
| 17,977 |
| | — |
| | — |
| | 17,977 |
| OPKO Lab | 32,988 |
| | — |
| | — |
| | 32,988 |
| | $ | 224,292 |
| | $ | — |
| | $ | (1,073 | ) | | $ | 223,219 |
|
|